App-Quantinova.ai

Phase 2 study of cabozantinib (cabo) and pembrolizumab (pembro) in metastatic gastric/gastroesophageal adenocarcinoma (mGEA) refractory to immune checkpoint inhibitors (ICIs).

Farshid Dayyani - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gastroesophageal junction (GEJ) adenocarcinoma

Pembrolizumab

First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients (pts) with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 Chinese subgroup analysis with 3-year follow-up.

Lin Shen - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gastroesophageal junction (GEJ) adenocarcinoma

Ipilimumab

Preliminary results of TQB2450 (PD-L1 blockade) plus anlotinib combined with oxaliplatin and capecitabine in the first-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: A single-arm, multicenter phase II clinical trial.

Ning Li - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2023

Therapeutic Area

Disease

Drug/Treatment

N/A

Capecitabine and oxaliplatin

Anlotinib combined with TQB2450 (PD-L1 blockade) as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, multicenter, open-label phase II clinical trial.

Xiuli Yang - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Esophageal squamous carcinoma cell

anlotinib

Interim results of a first-in-human phase 1 study of Q-1802, a CLDN18.2/PD-L1 bsABs, in patients with relapsed or refractory solid tumors.

Wang Yk - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Tislelizumab combined with anlotinib and chemotherapy (XELOX) in the treatment of advanced gastric carcinoma: Preliminary results of a single-arm, open-label phase I/IIa trial (TALENT study).

Xiaofeng Chen - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gastric Cancer

Tislelizumab

Phase II study of the combination of durvalumab, tremelimumab, and paclitaxel as second-line chemotherapy in biomarker-selected patients with metastatic gastric cancer.

Keun-Wook Lee - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gastric Cancer

Ticilimumab

Tumor microenvironment evaluation to predict anti–PD-1 response of advanced gastric cancer: Results from a multicenter prospective clinical trial.

Wangjun Liao - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Mismatch repair deficiency

N/A

Investigation of predictive biomarkers in patients treated with atezolizumab monotherapy following definitive chemoradiotherapy for unresectable locally advanced esophageal squamous cell carcinoma (EPOC1802).

Hideaki Bando - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Esophageal squamous carcinoma cell

Atezolizumab

Ex vivo oncolytic and immune activity of CF33-hNIS-antiPDL1 against fresh peritoneal cells from patients with gastric cancer with and without peritoneal metastases.

Zhifang Zhang - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gastric Cancer

N/A

Intertumor heterogeneity of locally advanced gastric cancer.

Natalia P. Belyak - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gastric Cancer

N/A

Molecular landscape and clinical implication of CCNE1-amplified esophagogastric cancer.

Ryan H. Moy - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Impact of infiltrating T cell subtypes on survival and response to FLOT chemotherapy in resectable oesophagogastric adenocarcinoma (OGA).

Avani Athauda - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2023

Therapeutic Area

Disease

Drug/Treatment

N/A

Primary results of the ICONIC phase 2 trial of perioperative FLOT plus avelumab (FLOT-A) in operable oesophagogastric adenocarcinoma (OGA).

Anderley Gordon - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2023

Therapeutic Area

Disease

Drug/Treatment

N/A

Avelumab

nextHERIZON: A phase 2 study of HER-Vaxx, a HER2-targeting peptide vaccine, in combination with chemotherapy or pembrolizumab in patients with HER2 metastatic or advanced gastric/gastroesophageal adenocarcinoma that progressed on or after trastuzumab treatment.

Timothy Jay Price - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gastroesophageal junction (GEJ) adenocarcinoma

Peptide vaccine

Penpulimab plus chemotherapy with or without anlotinib as first-line treatment for patients with advanced esophageal squamous cell carcinoma (ANSWER): A randomized, two-arm, clinical trial in progress.

Wei Wang - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Esophageal squamous carcinoma cell

Paclitaxel

Trial in progress: A phase 2, multicenter, open-label study of DKN-01 in combination with tislelizumab and chemotherapy as 1L therapy in patients with unresectable, locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ; DisTinGuish).

Keun-Wook Lee - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gastroesophageal junction (GEJ) adenocarcinoma

Tislelizumab

Comparison of anti–PD-L1 with anti–PD-1 antibodies in the combination of HAIC and lenvatinib for the treatment of unresectable hepatocellular carcinoma.

Shaohua Li - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

Durvalumab

A multicenter, single-arm, phase II study of nivolumab in patients with biliary tract cancer with a PD-L1 combined positive score ≥ 1.

Masayuki Furukawa - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Advanced biliary tract carcinoma

Nivolumab

Beyond CPS for PD-L1 scoring: Genetic alterations that impact efficacy of immunotherapy in hepatocellular carcinoma (HCC).

Emil Lou - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

N/A

Filters

4177 Abstracts